Teceos

Teceos contains 3,3-Diphosphono-1,2-Propanedicarboxylic Acid, Tetrasodium Salt (Dpd) for intravenous use. This radiopharmaceutical agent supports diagnostic imaging procedures by enhancing contrast in bone scans. Ideal for patients requiring detailed skeletal assessment.

Teceos is used to enhance the clarity of bone imaging scans, helping healthcare providers evaluate skeletal structures. It is commonly employed in diagnostic settings where detailed visualization of bones is required, such as detecting fractures, infections, or metastatic disease. The agent works by increasing contrast in areas with high bone metabolism.

After intravenous administration, Teceos distributes through the body and accumulates in areas of active bone formation. This accumulation enhances the visibility of bones during imaging procedures like scintigraphy. Patients may experience temporary warmth or flushing at the injection site, which is generally mild and short-lived.

Teceos should only be handled and administered by trained healthcare professionals. Patients with known allergies to phosphonates or similar compounds should inform their provider before use. Ensure proper hydration and monitor for any signs of adverse reactions during and after administration.

Limited data exists on drug interactions with Teceos. However, as a radiopharmaceutical, it is typically used in combination with other imaging agents or procedures. Patients should disclose all medications, including over-the-counter and supplements, to their healthcare provider to avoid potential conflicts.